Tag: Eylea biosimilar

Future Biosimilars: Upcoming Patent Expirations and Market Entry

Biosimilars are set to transform healthcare as major biologics like Keytruda and Eylea lose patent protection between 2025 and 2030. Learn how these complex, lower-cost alternatives are entering the market, what’s holding them back, and what it means for patients and providers.